Udar, Nitin http://orcid.org/0000-0001-8533-9190
Lofton-Day, Catherine
Dong, Jun
Vavrek, Darcy
Jung, A. Scott
Meier, Kristen
Iyer, Anita
Slaughter, Ryan
Gutekunst, Karen
Bach, Bruce A.
Peeters, Marc
Douillard, Jean-Yves
Funding for this research was provided by:
Amgen Inc
Illumina
Article History
Received: 9 March 2018
Accepted: 13 June 2018
First Online: 17 July 2018
Compliance with ethical standards
:
: N. Udar and R. Slaughter are former employees of and own stock in Illumina, Inc. D. Vavrek, K. Meier, A. Iyer, and K. Gutekunst are employees of and own stock in Illumina, Inc. C. Lofton-Day, J. Dong (and spouse), and A. S. Jung are employees of and own stock in Amgen Inc. B. A. Bach is a former employee of and owns stock in Amgen Inc. M. Peeters has received research funding from Amgen Inc. and Roche, and has served on speakers bureaus for Amgen Inc., Sanofi, Servier, and Bayer. J.-Y. Douillard has nothing to disclose.
: Samples were obtained from the PRIME study. All patients had given informed consent in the PRIME study, which was approved by responsible ethics committees and was carried out in accordance with the principles of good clinical practice and the Declaration of Helsinki. Details on ethics procedures can be found in the original PRIME study publication (Douillard et al.CitationRef removed).